Detailed Information on Publication Record
2017
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study
USTOHAL, Libor, Michaela MAYEROVÁ, Veronika HUBLOVÁ, Hana PŘIKRYLOVÁ KUČEROVÁ, Eva ČEŠKOVÁ et. al.Basic information
Original name
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study
Authors
USTOHAL, Libor (203 Czech Republic, guarantor, belonging to the institution), Michaela MAYEROVÁ (203 Czech Republic, belonging to the institution), Veronika HUBLOVÁ (203 Czech Republic, belonging to the institution), Hana PŘIKRYLOVÁ KUČEROVÁ (203 Czech Republic, belonging to the institution), Eva ČEŠKOVÁ (203 Czech Republic, belonging to the institution) and Tomáš KAŠPÁREK (203 Czech Republic, belonging to the institution)
Edition
Journal of Psychopharmacology, London, UK, SAGE Publications, 2017, 0269-8811
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30100 3.1 Basic medicine
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.738
RIV identification code
RIV/00216224:14740/17:00096842
Organization unit
Central European Institute of Technology
UT WoS
000400179400010
Keywords in English
Schizophrenia; cortical inhibition; cortical silent period; risperidone; transcranial magnetic stimulation
Tags
Tags
International impact, Reviewed
Změněno: 15/5/2018 09:03, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Objectives: Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP). It is thought that CSP measures gamma-aminobutyric acid receptors B (GABA(B)) mediated inhibitory activity. But the mutual roles of schizophrenia as a disease and the drugs used for the treatment of psychosis on GABA mediated neurotransmission are not clear. Methods: We recruited 13 drug-naive patients with first-episode schizophrenia. We used transcranial magnetic stimulation to assess CSP prior to initiating risperidone monotherapy and again four weeks later. At the same time, we rated the severity of psychopathology using the Positive and Negative Syndrome Scale (PANSS). Results: We obtained data from 12 patients who showed a significant increase in CSP, from 134.2041.81 ms to 162.95 +/- 61.98 ms (p=0.041; Cohen's d=0.544). After the treatment, the PANSS total score was significantly lower, as were the individual subscores (p<0.05). However, no correlation was found between CSP and PANSS. Conclusion: Our study in patients with first-episode schizophrenia demonstrated an association between risperidone monotherapy and an increase in GABA(B) mediated inhibitory neurotransmission.
Links
| LQ1601, research and development project |
|